312 related articles for article (PubMed ID: 16712904)
1. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W
Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
[TBL] [Abstract][Full Text] [Related]
2. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
Koestenberger M; Gallistl S; Muntean W; Leschnik B; Fritsch P; Cvirn G
Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786
[TBL] [Abstract][Full Text] [Related]
3. Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time.
Koestenberger M; Cvirn G; Gallistl S; Muntean W
Blood Coagul Fibrinolysis; 2004 Oct; 15(8):693-7. PubMed ID: 15613925
[TBL] [Abstract][Full Text] [Related]
4. Drotrecogin alfa (activated, Xigris) in combination with heparin or melagatran: an in vitro investigation.
Koestenberger M; Cvirn G; Gallistl S; Baier K; Leschnik B; Muntean W
J Thromb Thrombolysis; 2004 Aug; 18(1):5-10. PubMed ID: 15744547
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human activated protein C, heparin and melagatran in umbilical cord versus adult plasma.
Koestenberger M; Cvirn G; Gallistl S; Kutschera J; Muntean W
Acta Paediatr; 2005 Jul; 94(7):884-9. PubMed ID: 16188810
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulant action of melagatran: a comparison between neonates and adults using calibrated automated thrombography (CAT).
Cvirn G; Cimenti C; Kutschera J; Ferstl U; Wagner T; Muntean W; Jurgens G; Gallistl S; Koestenberger M
Eur J Pediatr; 2007 May; 166(5):427-31. PubMed ID: 17047995
[TBL] [Abstract][Full Text] [Related]
7. Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates.
Gruber A; Carlsson S; Kotzé HF; Marzec U; Sarich TC; Hanson SR
Thromb Res; 2007; 119(1):121-7. PubMed ID: 16448687
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination.
Koestenberger M; Gallistl S; Cvirn G; Baier K; Leschnik B; Muntean W
Thromb Res; 2005; 115(1-2):135-42. PubMed ID: 15567465
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin.
Furugohri T; Morishima Y
Thromb Res; 2015 Sep; 136(3):658-62. PubMed ID: 26188924
[TBL] [Abstract][Full Text] [Related]
10. Pravastatin potentiates the anticoagulant effects of low molecular weight heparin.
Zimmer JE; Spillert CR; Puppala S; Zamecki K; Bhatt BA; Arora RR
Thromb Res; 2004; 113(6):407-10. PubMed ID: 15226096
[TBL] [Abstract][Full Text] [Related]
11. A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats.
Elg M; Gustafsson D
Thromb Res; 2006; 117(4):429-37. PubMed ID: 15869787
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of factor IIa inhibitors on the endogenous thrombin potential.
Beilfuss A; Grandoch M; Wenzel F; Hohlfeld T; Schrör K; Weber AA
Ther Drug Monit; 2008 Dec; 30(6):740-3. PubMed ID: 18824953
[TBL] [Abstract][Full Text] [Related]
13. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma.
Boström SL; Hansson GF; Sarich TC; Wolzt M
Thromb Res; 2004; 113(1):85-91. PubMed ID: 15081569
[TBL] [Abstract][Full Text] [Related]
14. Effects of recombinant human activated protein C on the coagulation system: a study with rotational thromboelastometry.
Nilsson CU; Hellkvist PD; Engström M
Acta Anaesthesiol Scand; 2008 Oct; 52(9):1246-9. PubMed ID: 18823464
[TBL] [Abstract][Full Text] [Related]
15. A step change in oral anticoagulation: lack of coagulation monitoring with ximelagatran.
Carlsson SC; Schulman S
Semin Vasc Med; 2005 Aug; 5(3):259-65. PubMed ID: 16123913
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study.
Kuhle S; Lau A; Bajzar L; Vegh P; Halton J; Cherrick I; Anderson R; Desai S; McCusker P; Wu J; Abshire T; Mahoney D; Mitchell L
Br J Haematol; 2006 Sep; 134(5):526-31. PubMed ID: 16856890
[TBL] [Abstract][Full Text] [Related]
17. The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate.
Cosmi B; Agnelli G; Young E; Hirsh J; Weitz J
Thromb Haemost; 1993 Sep; 70(3):443-7. PubMed ID: 8259546
[TBL] [Abstract][Full Text] [Related]
18. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
19. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample.
Mattsson C; Menschiek-Lundin A; Wåhlander K; Lindahl TL
Thromb Haemost; 2001 Aug; 86(2):611-5. PubMed ID: 11522011
[TBL] [Abstract][Full Text] [Related]
20. A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate.
Sørensen B; Ingerslev J
Thromb Haemost; 2006 Oct; 96(4):446-53. PubMed ID: 17003921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
